# Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

Study · id `cardio:ct-nct01538446` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01538446](<https://clinicaltrials.gov/study/NCT01538446>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01538446

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 880 participants.

## Technical summary

Registry record NCT01538446. Randomized; no masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2016-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 880 participants (enrolled count; ClinicalTrials.gov record NCT01538446, source copy `cardio:ctgov-nct01538446-2017-01-11`, retrieved 2026-10-31)
- Start date: 2012-03 (registry gives no type) (ClinicalTrials.gov record NCT01538446, source copy `cardio:ctgov-nct01538446-2017-01-11`, retrieved 2026-10-31)
- Primary completion: 2016-05 (actual) (ClinicalTrials.gov record NCT01538446, source copy `cardio:ctgov-nct01538446-2017-01-11`, retrieved 2026-10-31)
- Completion: 2016-05 (actual) (ClinicalTrials.gov record NCT01538446, source copy `cardio:ctgov-nct01538446-2017-01-11`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT01538446, source copy `cardio:ctgov-nct01538446-2017-01-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01538446-2017-01-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
- Acronym: ANTARCTIC
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Modification of Prasugrel based on a biological assay
- Intervention (Drug): prasugrel / clopidogrel
- Intervention (Device): Verify Now
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY
- Collaborator: Daiichi Sankyo
- Collaborator class: INDUSTRY
- Collaborator: Allies in Cardiovascular Trials Initiatives and Organized
- Collaborator class: OTHER
- Collaborator: Accumetrics, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Stentys
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)
- Registry lists this organization as a collaborator: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial (`cardio:pubmed-27581531`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial (`cardio:pubmed-34191259`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4cd7c55c7afd045d15cc6d0445fbd7e1cfb3de969a9d3a46579f9d0322b58b0f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
